<DOC>
	<DOCNO>NCT00355407</DOCNO>
	<brief_summary>The purpose study find Darbepoetin alfa effective treat low red blood cell level allogeneic stem cell transplant . Darbepoetin alfa show help raise red blood cell level without blood transfusion .</brief_summary>
	<brief_title>Darbepoetin Alfa ( Aranesp ) Following Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>- Participants receive Darbepoetin alfa injection skin , 28-35 day allogeneic stem cell transplant . They continue receive study drug every three week maximum four dos . - Blood test perform week 3 , 6 , 9 12 . The blood test do week three check make sure participant enough iron system . If , need take iron supplement . Participants also take folate supplement help cell growth reproduction .</detailed_description>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Hematologic malignancy undergo ablative allogeneic stem cell transplantation indication 18 year age old Hgb less 10 g/dL time initiation therapy Known hypersensitivity reaction darbepoetin alfa component Transfusion pack red blood cell within 3 day initiation treatment darbepoetin alfa Any history grade III IV GVHD Use erythropoietic growth factor since transplantation Uncontrolled hypertension History seizure Baseline creatinine great 2 Dialysis dependence time enrollment Hemolytic uremic syndrome Active GI bleed Concurrent autoimmune hemolytic anemia Concurrent unstable angina History congenital hypercoagulable state previous venous arterial thrombosis Relapsed disease prior initiation study treatment History renal cell carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Aranesp</keyword>
	<keyword>allogeneic stem cell transplant</keyword>
</DOC>